Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6429189B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 10, 1999 |
| Grant date | Aug 6, 2002 |
| Priority date | — |
| Expiry date | Dec 10, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/842
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical applications of a chemodenervating agent reduce pain by altering release of pain and inflammation-mediating autocoids, with a duration of action between 12-24 weeks. The limiting factor in dosing for this application is weakness and paralysis created by higher doses of the chemodenervating pharmaceutical. This weakness and paralysis is mediated by action of the neurotoxin component of the chemodenervating pharmaceutical. The invention described herein represents a novel mechanism and pharmaceutical formulation which eliminates the neurotoxin component of the chemodenervating pharmaceutical, while retaining the cytotoxin component which provides an essential bioeffect for the relief of pain and inflammation. The invention allows for improvement in administering the pharmaceutical agent for the reduction of pain and/or inflammation without causing muscular weakness and paralysis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.